CASE REPORT
Radiotherapy-Related Dural Sarcoma and Its Management: Case Report
Received Date : 02 Jun 2020
Accepted Date : 24 Nov 2020
Available Online : 11 Dec 2020
Mustafa GÜRBÜZa, Pınar Kubilay TOLUNAYa, Erman AKKUŞb, Ümit EROĞLUc, Aylin Okçu HEPERd, Filiz ÇAY ŞENLERa
aAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
bAnkara University Faculty of Medicine, Department of Internal Medicine, Ankara, TURKEY
cAnkara University Faculty of Medicine, Department of Neurosurgery, Ankara, TURKEY
dAnkara University Faculty of Medicine, Department of Pathology, Ankara, TURKEY
Doi: 10.37047/jos.2020-76458 - Article's Language: EN
J Oncol Sci. 2020;6(3):179-82
ABSTRACT
Sarcomas are malignant neoplasms that arise from mesenchymal tissues. Sarcomas of the meninges may originate primarily from
mesenchymal cells or may be metastases of extracranial soft tissue sarcomas. Radiotherapy (RT)-related dural sarcomas are extremely rare,
and the prognosis of RT-related sarcoma patients is worse than that of primary sarcoma. There is no consensus about the management of
these very rare, malignant neoplasms. The authors herein report a patient with dural sarcoma and its management. Although the main treatment
is surgery, re-irradiation, conventional chemotherapeutics, and targeted therapies are other options. Long term side effects of treatments
should always be kept in mind and treatment decisions should be made accordingly.
Keywords: Sarcoma; dura mater; radiotherapy; antineoplastic protocols
REFERENCES
- Ferrari A, Dirksen U, Bielack S. Sarcomas of soft tissue and bone. Prog Tumor Res. 2016;43:128-141. [Crossref] [PubMed]
- Yamanaka R, Hayano A. Radiation-induced sarcomas of the central nervous system: a systematic review. World Neurosurg. February 2017;98:818-828. [Crossref] [PubMed]
- Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200-229. [Crossref] [PubMed]
- Chowdhary A, Spence AM, Sales L, Rostomily RC, Rockhill JK, Silbergeld DL. Radiation associated tumors following therapeutic cranial radiation. Surg Neurol Int. 2012;3:48. [Crossref] [PubMed] [PMC]
- Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res. 2012;2(1):18. [Crossref] [PubMed] [PMC]
- Laskin WB, Silverman TA, Enzinger FM. Postradiation soft tissue sarcomas. An analysis of 53 cases. Cancer. 1988;62(11):2330-2340. [Crossref] [PubMed]
- Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Smeland S, Fosså SD. Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival? Br J Cancer. 2012;106(2):297-306. [Crossref] [PubMed] [PMC]
- Hemmati SM, Ghadjar P, Grün A, et al. Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma. Radiat Oncol. 2019;14(1):160. [Crossref] [PubMed] [PMC]
- Peterson RA, Kashyap B, Pawloski PA, Forsberg AC, Hanson LR. Unique case report of a meningeal sarcoma arising during ongoing treatment for progressing intraparenchymal glioma. Case Rep Oncol Med. November 2019;2019:7950782. [Crossref] [PubMed] [PMC]
- Zhang GB, Li J, Zhang PF, Han LJ, Zhang JT. Radiation-induced malignant fibrous histiocytoma of the occipital: a case report. World J Surg Oncol. April 2014;12:98. [Crossref] [PubMed] [PMC]
- Bojsen-Moller M, Knudsen V. Radiation-induced meningeal sarcoma. A case report with a review of the literature. Acta Neurochir (Wien). 1977;37(1-2):147-152. [Crossref] [PubMed]
- Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573-581. [Crossref] [PubMed]
- Nathenson MJ, Conley AP, Sausville E. Immunotherapy: a new (and Old) approach to treatment of soft tissue and bone sarcomas. Oncologist. 2018;23(1):71-83. [Crossref] [PubMed] [PMC]
- Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-282. [Crossref] [PubMed] [PMC]
JOURNAL of
EN